Section Arrow
AGEN.NASDAQ
- Agenus
Quotes are at least 15-min delayed:2025/05/29 15:22 EDT
Last
 3.11
+0.09 (+2.98%)
Day High 
3.18 
Prev. Close
3.02 
1-M High
4.0597 
Volume 
354.85K 
Bid
3.1
Ask
3.12
Day Low
2.9601 
Open
3.03 
1-M Low
2.7 
Market Cap 
82.80M 
Currency USD 
P/E 0.1 
%Yield -- 
10-SMA 3.58 
20-SMA 3.33 
50-SMA 2.5 
52-W High 19.688 
52-W Low 1.38 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
29.61/-2.67
Enterprise Value
167.82M
Balance Sheet
Book Value Per Share
-12.47
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
103.46M
Operating Revenue Per Share
3.62
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ALZNAlzamend Neuro Inc.5.49+2.17+65.36%-- 
ENTOEntero Therapeutics Inc.0.40485+0.01085+2.75%0.03PE
NCNANuCana plc0.03545-0.00205-5.47%-- 
IMNNImunon2.1405+0.6205+40.82%-- 
NTLAIntellia Therapeutics7.32-2.34-24.22%-- 
Quotes are at least 15-min delayed:2025/05/29 15:22 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.